文献速递创伤与烧伤消化、代谢与肾脏急症

创伤患者肠吻合术后使用非甾体抗炎药是否安全

Is the use of nonsteroidal anti-inflammatories after bowel anastomosis in trauma safe?
PubMed 文献 · J Trauma Acute Care Surg · 2023-01-19
一句话结论创伤肠吻合术后使用非甾体抗炎药未显著增加吻合口并发症,但合并其他危险因素时可能与吻合口漏风险增加相关,应谨慎使用。

本研究回顾性分析了2011年至2017年一家一级创伤中心295例因创伤行肠切除吻合的患者,其中192例使用非甾体抗炎药(NSAIDs)。经倾向性权重调整后,NSAIDs不是吻合口并发症的主要预测因素(p=0.39),但与吻合口漏存在弱关联(OR 1.92,95%CI 0.97-3.90,p=0.06)。围手术期使用血管升压药与吻合口漏风险增加相关(OR 3.33,95%CI 1.17-9.05,p<0.001),24小时内红细胞输注量增加与腹腔内并发症相关(OR 1.02,95%CI 1.00-1.04,p=0.05)。作者认为,在存在其他明确危险因素的情况下,创伤患者使用NSAIDs可能与吻合口漏风险增加相关,应谨慎使用。

要点

  • 倾向性权重调整后,NSAIDs不是吻合口并发症的主要预测因素(p=0.39)。
  • 围手术期使用血管升压药与吻合口漏风险增加相关(OR 3.33,95%CI 1.17-9.05,p<0.001)。
  • 24小时内红细胞输注量增加与腹腔内并发症相关(OR 1.02,95%CI 1.00-1.04,p=0.05)。
  • NSAIDs与吻合口漏存在弱关联(OR 1.92,95%CI 0.97-3.90,p=0.06)。
  • 作者认为,在存在其他明确危险因素时,创伤患者使用NSAIDs可能与吻合口漏风险增加相关,应谨慎使用。

适用人群与场景

  • 2011年至2017年就诊于一家一级创伤中心、因创伤需行肠切除吻合的患者。

研究设计与关键结果

  • 研究类型:回顾性研究;样本量:295例,其中192例使用NSAIDs;单中心(一家一级创伤中心)。
  • 使用NSAIDs的患者腹部简明损伤定级和损伤严重度评分较低(p<0.046)。
  • 使用NSAIDs的患者到达时收缩压、舒张压和格拉斯哥昏迷评分较高(p<0.013)。
  • 经倾向性权重调整后,NSAIDs不是吻合口并发症的主要预测因素(p=0.39)。
  • 围手术期使用血管升压药与吻合口漏风险增加相关(OR 3.33,95%CI 1.17-9.05,p<0.001)。
  • 24小时内红细胞输注量增加与腹腔内并发症相关(OR 1.02,95%CI 1.00-1.04,p=0.05)。
  • NSAIDs与吻合口漏存在弱关联(OR 1.92,95%CI 0.97-3.90,p=0.06)。

证据类型、等级与局限

  • 证据类型:回顾性研究;证据等级:治疗/管理,Level III。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在存在其他明确危险因素(如围手术期使用血管升压药、24小时内红细胞输注量增加)的情况下,创伤患者使用NSAIDs可能与吻合口漏风险增加相关,应谨慎使用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: With an increasing interest in multimodal and opioid-reducing pain strategies, nonsteroidal anti-inflammatory drugs (NSAIDs) have become common place in the care of injured patients. Long-standing concerns of increased anastomotic leak (AL) rate with the use of NSAIDs, however, have persisted. We hypothesized that there would be no significant risk associated with NSAID use after bowel anastomosis in trauma patients.

METHODS: All patients presenting to a level 1 trauma center who required intestinal resection and anastomosis from 2011 to 2017 were reviewed. Patients receiving NSAIDs were compared with those managed without NSAIDs. Primary outcome of interest was anastomosis-related complications (AL, intra-abdominal abscess, anastomotic bleed, fascial dehiscence, fascial dehiscence, and enterocutaneous fistula). Multivariable logistic regression analyses were performed with propensity adjustment for inverse probability of NSAID treatment weights.

RESULTS: A total of 295 patients met the inclusion criteria with 192 receiving NSAIDs. Patients receiving NSAIDs had lower abdominal Abbreviated Injury Scale and Injury Severity Score ( p < 0.046). Arrival systolic blood pressure, diastolic blood pressure, and Glasgow Coma Scale were higher in the NSAID group ( p < 0.013). After propensity weighting, NSAID use was not a major predictor of anastomotic complication ( p = 0.39). There was an increased risk of AL with perioperative vasopressor exposure (odds ratio [OR], 3.33; 95% confidence interval [CI], 1.17-9.05; p < 0.001). Increasing red blood cell transfusions in the first 24 hours were associated with intra-abdominal complications (OR, 1.02; 95% CI, 1.00-1.04; p = 0.05). Nonsteroidal anti-inflammatory drug exposure demonstrated a weak association with AL (OR, 1.92; 95% CI, 0.97-3.90; p = 0.06).

CONCLUSION: Consistent with previous studies, perioperative vasopressor exposure and increased number of red blood cell transfusions are risk factors for ALs and intra-abdominal complications, respectively. Nonsteroidal anti-inflammatory drug use in trauma patients with multiple risk factors may be associated with an increased risk of AL and should be used with caution in the setting of other established risk factors.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Clements TW, Van Gent JM, Hatton GE, et al. Is the use of nonsteroidal anti-inflammatories after bowel anastomosis in trauma safe? J Trauma Acute Care Surg. 2023. PMID: 36728125. doi:10.1097/TA.0000000000003872

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。